Review on Advanced Cancer Modeling for a Cancer Study

Overview

Journal Curr Issues Mol Biol

Publisher MDPI

Specialty Molecular Biology

Date 2022 Nov 10

PMID 36354674

Authors

Yong-Hee Cho

Affiliations

Soon will be listed here.

Abstract

Intensive efforts to develop anti-cancer agents have been made for over 60 years. However, cancer is still considered a lethal disease. To study the best anti-cancer agents for improving the survival rates of cancer patients, many researchers have focused on establishing advanced experimental applications reflecting on the biomimetics of cancer patients involving the heterogeneity of cancer cells. The heterogeneity of cancer cells, which are derived from various clones and affected by different environments, presents different genetic backgrounds and molecular characteristics attributed to the differential responses to cancer therapies, and these are responsible for the resistance to cancer therapies, as well as for recurrence following cancer treatments. Therefore, the development of advanced applications for the cancer patient is expected to help the development of more effective anti-cancer agents. The present review evaluates recently developed cancer models encompassing the heterogeneity of cancer cells, which present similar morphological architecture, genetic backgrounds, and molecular characteristics to corresponding patient tumor tissues.

References

Shiihara M, Furukawa T . Application of Patient-Derived Cancer Organoids to Personalized Medicine. J Pers Med. 2022; 12(5). PMC: 9146789. DOI: 10.3390/jpm12050789. View

Pham N, Radulovich N, Ibrahimov E, Martins-Filho S, Li Q, Pintilie M . Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. Sci Rep. 2021; 11(1):10619. PMC: 8134568. DOI: 10.1038/s41598-021-90049-1. View

Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F . A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2017; 172(1-2):373-386.e10. DOI: 10.1016/j.cell.2017.11.010. View

Dong X, Guan J, English J, Flint J, Yee J, Evans K . Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res. 2010; 16(5):1442-51. DOI: 10.1158/1078-0432.CCR-09-2878. View

Bartfeld S, Bayram T, van de Wetering M, Huch M, Begthel H, Kujala P . In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. Gastroenterology. 2014; 148(1):126-136.e6. PMC: 4274199. DOI: 10.1053/j.gastro.2014.09.042. View

Choi S, Cho Y, Kim D, Ji W, Choi C, Lee J . Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids. Int J Mol Sci. 2021; 22(3). PMC: 7866263. DOI: 10.3390/ijms22031349. View

Barker N, Huch M, Kujala P, van de Wetering M, Snippert H, van Es J . Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell. 2010; 6(1):25-36. DOI: 10.1016/j.stem.2009.11.013. View

Campbell P, Yachida S, Mudie L, Stephens P, Pleasance E, Stebbings L . The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467(7319):1109-13. PMC: 3137369. DOI: 10.1038/nature09460. View

John T, Kohler D, Pintilie M, Yanagawa N, Pham N, Li M . The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res. 2010; 17(1):134-41. DOI: 10.1158/1078-0432.CCR-10-2224. View

10.

Kinzler K, Vogelstein B . Lessons from hereditary colorectal cancer. Cell. 1996; 87(2):159-70. DOI: 10.1016/s0092-8674(00)81333-1. View

11.

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

12.

Sun X, Yu Q . Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol Sin. 2015; 36(10):1219-27. PMC: 4648179. DOI: 10.1038/aps.2015.92. View

13.

Lo Y, Karlsson K, Kuo C . Applications of Organoids for Cancer Biology and Precision Medicine. Nat Cancer. 2021; 1(8):761-773. PMC: 8208643. DOI: 10.1038/s43018-020-0102-y. View

14.

Boonekamp K, Kretzschmar K, Wiener D, Asra P, Derakhshan S, Puschhof J . Long-term expansion and differentiation of adult murine epidermal stem cells in 3D organoid cultures. Proc Natl Acad Sci U S A. 2019; 116(29):14630-14638. PMC: 6642409. DOI: 10.1073/pnas.1715272116. View

15.

Mattie M, Christensen A, Chang M, Yeh W, Said S, Shostak Y . Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia. 2013; 15(10):1138-50. PMC: 3819630. DOI: 10.1593/neo.13922. View

16.

Kondo J, Inoue M . Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. Cells. 2019; 8(5). PMC: 6562517. DOI: 10.3390/cells8050470. View

17.

Scott C, Becker M, Haluska P, Samimi G . Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol. 2013; 3:295. PMC: 3849703. DOI: 10.3389/fonc.2013.00295. View

18.

Kopetz S, Lemos R, Powis G . The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res. 2012; 18(19):5160-2. PMC: 4217576. DOI: 10.1158/1078-0432.CCR-12-2408. View

19.

Qi Z, Li Y, Zhao B, Xu C, Liu Y, Li H . BMP restricts stemness of intestinal Lgr5 stem cells by directly suppressing their signature genes. Nat Commun. 2017; 8:13824. PMC: 5227110. DOI: 10.1038/ncomms13824. View

20.

Dalerba P, Dylla S, Park I, Liu R, Wang X, Cho R . Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007; 104(24):10158-63. PMC: 1891215. DOI: 10.1073/pnas.0703478104. View